ロード中...
RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer
BACKGROUND: RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for RAS amplification (RASa) as a biomarker for anti‐EGFR therapy in CRC remain i...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8176984/ https://ncbi.nlm.nih.gov/pubmed/33465286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13679 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|